サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405793

ゴーシェ病治療薬の市場規模、シェア、動向分析レポート：タイプ別、治療別、地域別、セグメント予測、2023年～2030年

Gaucher Disease Drugs Market Size, Share & Trends Analysis Report By Type (Type 1, Type 2, Type 3, Others) By Therapy (Enzyme Replacement Therapy, Substrate Replacement Therapy, Others), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 84 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ゴーシェ病治療薬の市場規模、シェア、動向分析レポート：タイプ別、治療別、地域別、セグメント予測、2023年～2030年
出版日: 2023年12月06日
発行: Grand View Research
ページ情報: 英文 84 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ゴーシェ病治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のゴーシェ病治療薬市場規模は2023年から2030年にかけてCAGR 2.6%で拡大し、2030年には20億3,000万米ドルに達する見込みです。

同疾患の有病率の高まりと、同分野における研究開発活動の活発化が、今後数年間の同市場の勢いを増す一助となりそうです。アンメットニーズが高いことから、神経細胞障害性合併症に対する有効性の改善、簡便な投与、コスト削減を実現する新規治療法の開発が強く求められています。

ゴーシェ病は、GBA遺伝子の変異によって引き起こされる遺伝性代謝疾患です。ゴーシェ病患者は、グルコセレブロシドを分解するのに必要な酵素であるグルコセレブロシダーゼ（GCase）の産生量が少ないです。脾臓、肝臓、腎臓、脳、肺、骨髄に脂質が過剰に蓄積し、臓器の正常な機能を阻害します。

ゴーシェ病は、ライソゾーム貯蔵異常症の中で最も頻度の高い疾患であるにもかかわらず、平均有病率は10万人に1人という稀な疾患です。しかし、アシュケナージ・ユダヤ人のような特定の民族はこの疾患に罹患しやすいです。アシュケナージ・ユダヤ人の平均有病率は500人に1人です。

現在、ゴーシェ病の最も一般的な病型は1型です。この疾患は中枢神経系（CNS）に影響を及ぼさないため、本質的に非神経障害性です。1型GDは2017年に市場の75.0％以上を占めました。2025年までその地位を維持すると推定されます。2型と3型は1型ほど一般的ではないです。

治療法別では、酵素補充療法（ERT）が2017年の市場収益貢献の主役でした。このセグメントの成長は、セレザイムとVprivの好調な売上に起因しています。しかし、CerdelgaとZavescaに先導された基質置換療法（SRT）への傾斜が増加しています。ERTは、補充酵素が血液脳関門を通過できないため、主に1型と3型（中枢神経系とは無関係の問題に対処するため）に適応されます。また、2型には有効な治療法がないです。

ゴーシェ病治療薬市場レポート・ハイライト

  • 2型はGDの3つの型の中で最も稀であり、平均死亡率は2年未満です。
  • サノフィ・ジェンザイム社のセレザイムを筆頭に、酵素補充療法が治療の主流を占めています。しかし、GD治療は基質置換療法へとシフトしつつあります。
  • 米国は、売上高と疾病負担の両面で主要市場をリードしています。同国は、患者層の拡大と治療へのアクセスのしやすさから、2030年まで市場を独占し続けると思われます。
  • 市場に参入している著名な企業には、サノフィ・ジェンザイム、シャイアー、ファイザー、ジョンソン・エンド・ジョンソンがあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ゴーシェ病治療薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ゴーシェ病治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 ゴーシェ病治療薬：タイプの推定・動向分析

  • ゴーシェ病治療薬市場：重要なポイント
  • ゴーシェ病治療薬市場：動向と市場シェア分析、2022年および2030年
  • タイプ1
  • タイプ2
  • タイプ3
  • その他

第5章 ゴーシェ病治療薬：治療の推定・動向分析

  • ゴーシェ病治療薬市場：重要なポイント
  • ゴーシェ病治療薬市場：動向と市場シェア分析、2022年および2030年
  • 酵素補充療法
  • 基質交換療法
  • その他

第6章 ゴーシェ病治療薬市場：地域の推定・動向分析

  • 地域別の見通し
  • 地域別のゴーシェ病治療薬市場：主要なマーケットプレースのポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Sanofi
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc
    • Johnson & Johnson Services, Inc.
    • ERAD Therapeutic
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 3 North America Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 4 North America Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 Canada Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 8 Canada Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 9 Europe Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 10 Europe Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 Europe Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 UK Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 13 UK Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 Germany Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 15 Germany Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 16 France Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 17 France Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 18 Italy Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 19 Italy Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 20 Spain Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 21 Spain Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 22 Sweden Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 23 Sweden Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 24 Norway Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 25 Norway Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 26 Denmark Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 27 Denmark Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 China Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 32 China Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 33 Japan Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 34 Japan Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 35 India Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 36 India Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 37 Australia Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 38 Australia Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 39 Thailand Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 40 Thailand Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 41 South Korea Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 42 South Korea Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 43 Latin America Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 44 Latin America Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 45 Latin America Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 47 Brazil Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 48 Mexico Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 49 Mexico Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 50 Argentina Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 51 Argentina Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 57 South Africa Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 58 South Africa Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 59 UAE Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 60 UAE Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Gaucher disease drugs: Market outlook
  • Fig. 9 Gaucher disease drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Gaucher disease drugs market driver impact
  • Fig. 15 Gaucher disease drugs market restraint impact
  • Fig. 16 Gaucher disease drugs market strategic initiatives analysis
  • Fig. 17 Gaucher disease drugs market: Type movement analysis
  • Fig. 18 Gaucher disease drugs market: Type outlook and key takeaways
  • Fig. 19 Type 1 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Type 2 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Type 3 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Gaucher disease drugs market: Therapy movement analysis
  • Fig. 24 Gaucher disease drugs market: Therapy outlook and key takeaways
  • Fig. 25 Enzyme replacement therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Substrate replacement therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Global gaucher disease drugs market: Regional movement analysis
  • Fig. 29 Global gaucher disease drugs market: Regional outlook and key takeaways
  • Fig. 30 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-599-1

Gaucher Disease Drugs Market Growth & Trends:

The global gaucher disease drugs market size is expected to reach USD 2.03 billion by 2030, expanding at a CAGR of 2.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for the development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.

Gaucher disease is a genetic metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme required to degrade glucocerebroside. Excess accumulation of lipids in spleen, liver, kidney, brain, lungs, and bone marrow impedes the normal functioning of the organs.

In spite of being the most prevalent lysosomal storage disorder, Gaucher disease is a rare condition with an average prevalence of 1 in 100,000 individuals. However, certain ethnic races such as Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an average disease prevalence of 1 in 500 individuals.

Currently, type 1 is the most common form of Gaucher disease. This condition is nonneuronopathic in nature, as it does not affect the central nervous system (CNS). Type 1 GD commanded more than 75.0% of the market in 2017. It is estimated to retain its position through 2025. Type 2 and type 3 are not as common as type 1.

On the basis of treatment, enzyme replacement therapy (ERT) was the leading revenue contributor in the market in 2017. The growth of the segment can be attributed to the strong sales of Cerezyme and Vpriv. However, there has been an increase in inclination towards substrate replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly indicated for type 1 and type 3 (to address issues unrelated to the CNS), as replacement enzymes cannot penetrate blood brain barrier. Additionally, there is no effective treatment for type 2.

Gaucher Disease Drugs Market Report Highlights:

  • Type 2 is the rarest of the three forms of GD, with an average mortality rate of less than two years
  • Enzyme replacement therapy dominated the treatment landscape, headed by Sanofi Genzyme's Cerezyme. However, GD treatment is witnessing a shift towards substrate replacement therapy
  • The U.S. spearheaded the major markets, in terms of sales as well as disease burden. The country will continue to dominate the market through 2030, on account of widening the patient base and easy accessibility to treatments
  • Some of the prominent companies operating in the market are Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Therapy
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Therapy outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Gaucher Disease Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Gaucher Disease Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Gaucher Disease Drugs: Type Estimates & Trend Analysis

  • 4.1. Gaucher Disease Drugs Market: Key Takeaways
  • 4.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Type 1
    • 4.3.1. Type 1 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Type 2
    • 4.4.1. Type 2 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Type 3
    • 4.5.1. Type 3 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Gaucher Disease Drugs: Therapy Estimates & Trend Analysis

  • 5.1. Gaucher Disease Drugs Market: Key Takeaways
  • 5.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Enzyme Replacement Therapy
    • 5.3.1. Enzyme replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Substrate Replacement Therapy
    • 5.4.1. Substrate replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Gaucher Disease Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Gaucher Disease Drugs Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Sanofi
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Takeda Pharmaceutical Company Limited
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Pfizer Inc
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Johnson & Johnson Services, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. ERAD Therapeutic
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives